CSTL
Castle Biosciences, Inc.
Set alert
37.16 USD -1.35 -3.51%
36.73 Day range 38.43
18.15 52-week range 43.04
- YTD
- -4.47%
- 1 year
- +53.49%
- Open
- 38.03
- Prev close
- 38.51
- Mkt cap
- 1.14B
- Vol
- 334.26K
- Avg vol
- 399.33K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 36.73
- High
- 38.43
- Forward P/E
- -39.74
- Beta
- 0.94
- Short ratio
- 5.17
- Inst. own
- 91.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 34.13
- 200-d avg
- 28.54
- 1y target
- 46.70
Financial health
Altman Z-Score
8.01 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 4
Valuation
P/E -46.9×
FY 2017 5y median -10.1× FY 2025
P/S 3.3×
FY 2017 5y median 3.3× FY 2025
P/B 2.4×
FY 2017 5y median 1.6× FY 2025
P/FCF 39.8×
FY 2017 5y median -13.0× FY 2025
EV/EBITDA 92.4×
FY 2017 5y median -8.6× FY 2025
EV/Sales 3.0×
FY 2017 5y median 3.0× FY 2025
FCF Yield 2.5%
FY 2017 5y median -2.1% FY 2025
Profitability
Gross Margin 79.4%
FY 2017 5y median 79.5% FY 2025
Operating Margin -12.4%
FY 2017 5y median -30.9% FY 2025
Net Margin -7.0%
FY 2017 5y median -26.1% FY 2025
ROE -5.1%
FY 2017 5y median -7.6% FY 2025
ROIC -6.8%
FY 2017 5y median -7.1% FY 2025
ROA -4.2%
FY 2017 5y median -6.8% FY 2025
Growth (YoY)
Revenue 3.7%
FY 2017 FY 2025
Operating Income -593.8%
FY 2017 FY 2025
EPS (diluted) -233.9%
FY 2017 FY 2025
Free Cash Flow -22.5%
FY 2017 FY 2025
Financial Health
Current Ratio 5.3×
FY 2017 5y median 7.3× FY 2025
Quick Ratio 5.1×
FY 2017 5y median 7.1× FY 2025
Debt / Equity 0.1×
FY 2017 5y median 0.0× FY 2025
Net Debt / EBITDA -7.0×
FY 2017 5y median 1.9× FY 2025
Interest Coverage -498×
FY 2017 5y median -4286× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31